Alterity Therapeutics is a development stage enterprise engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. Co. is developing therapies to treat neurodegenerative diseases. Co.'s primary drug candidate, ATH434 is for treatment of Parkinson's disease. Other applications for Co.'s compounds include the treatment or amelioration of neurodegenerative disorders such as tauopathies, Motor Neuron disease, Creutzfeldt-Jakob disease, certain cancers, age-related macular degeneration, or antibiotic resistance. The ATHE stock yearly return is shown above.
The yearly return on the ATHE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ATHE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|